Literature DB >> 2225314

Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity.

L L Tsang1, P B Farmer, A Gescher, J A Slack.   

Abstract

The experimental antineoplastic agent temozolomide was not metabolised in vitro at a measurable rate by mouse liver fractions. In contrast, the temozolomide analogue 3-methylbenzotriazinone was metabolically N-demethylated by hepatic microsomes to yield benzotriazinone. The major route of excretion of [14C]-labelled temozolomide in mice was via the kidneys. An acidic metabolite of temozolomide, probably a conjugate, was found in the urine of mice, but its identity could not be established unambiguously. Spectroscopic analysis and chemical tests revealed that it possesses an intact NNN-linkage. Another metabolite was found in the urine of patients but not of mice. This metabolite was identified as the 8-carboxylic acid derivative of temozolomide. Unlike the unknown species, this metabolite was cytotoxic against TLX5 lymphoma cells in vitro.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2225314     DOI: 10.1007/bf02994094

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  Solid phase extraction chromatography and NMR spectroscopy (SPEC-NMR) for the rapid identification of drug metabolites in urine.

Authors:  I D Wilson; J K Nicholson
Journal:  J Pharm Biomed Anal       Date:  1988       Impact factor: 3.935

2.  High-performance liquid chromatographic method with fluorescence detection for the simultaneous determination of metopimazine and its acid metabolite in serum.

Authors:  H R Angelo; J Herrstedt; M Jørgensen
Journal:  J Chromatogr       Date:  1989-11-24

3.  Anti-tumour imidazotetrazines. Part XXI. Mitozolomide and temozolomide: probes for the major groove of DNA.

Authors:  A S Clark; M F Stevens; C E Sansom; C H Schwalbe
Journal:  Anticancer Drug Des       Date:  1990-02

4.  Identification by nuclear magnetic resonance and mass spectrometry of a glucuronic acid conjugate of o-hydroxybenzoic acid in normal urine and uremic plasma.

Authors:  J P Monti; P Gallice; A Crevat; A Murisasco
Journal:  Clin Chem       Date:  1985-10       Impact factor: 8.327

5.  Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

Authors:  M F Stevens; J A Hickman; S P Langdon; D Chubb; L Vickers; R Stone; G Baig; C Goddard; N W Gibson; J A Slack
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

6.  High-performance liquid chromatographic separation, isolation and identification of 1,2,3-thiadiazole-5-carboxaldoxime glucuronide in rabbit urine.

Authors:  A Verweij; C E Kientz
Journal:  J Chromatogr       Date:  1981-11-13

7.  Antitumor imidazotetrazines. 20. Preparation of the 8-acid derivative of mitozolomide and its utility in the preparation of active antitumor agents.

Authors:  K R Horspool; M F Stevens; C G Newton; E Lunt; R J Walsh; B L Pedgrift; G U Baig; F Lavelle; C Fizames
Journal:  J Med Chem       Date:  1990-05       Impact factor: 7.446

Review 8.  The generation of potentially toxic, reactive iminium ions from the oxidative metabolism of xenobiotic N-alkyl compounds.

Authors:  M Overton; J A Hickman; M D Threadgill; K Vaughan; A Gescher
Journal:  Biochem Pharmacol       Date:  1985-06-15       Impact factor: 5.858

9.  A compound from uremic plasma and from normal urine isolated by liquid chromatography and identified by nuclear magnetic resonance.

Authors:  P Gallice; J P Monti; A Crevat; C Durand; A Murisasco
Journal:  Clin Chem       Date:  1985-01       Impact factor: 8.327

10.  Structure determination of metabolites of rilmazafone, a 1H-1,2,4-triazolyl benzophenone derivative in monkey urine.

Authors:  M Koike; R Norikura; K Iwatani; K Sugeno; S Takahashi; Y Nakagawa
Journal:  Xenobiotica       Date:  1988-03       Impact factor: 1.908

View more
  20 in total

1.  Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution.

Authors:  Kuo-Liang Chiang; Kai-Ping Chang; Yi-Yen Lee; Pin-I Huang; Ting-Rong Hsu; Yi-Wei Chen; Feng-Chi Chang; Tai-Tong Wong
Journal:  Childs Nerv Syst       Date:  2010-03-10       Impact factor: 1.475

2.  Population pharmacokinetics of temozolomide in cancer patients.

Authors:  J F Jen; D L Cutler; S M Pai; V K Batra; M B Affrime; D N Zambas; S Heft; G Hajian
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

3.  Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.

Authors:  Els Everaert; Bart Neyns; Eric Joosens; Theo Strauven; Fabrice Branle; Johan Menten
Journal:  J Neurooncol       Date:  2004-10       Impact factor: 4.130

4.  The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection.

Authors:  Rujun Li; Dongfang Tang; Jinshi Zhang; Jinding Wu; Ling Wang; Jun Dong
Journal:  J Neurooncol       Date:  2013-09-25       Impact factor: 4.130

5.  Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.

Authors:  L L Tsang; C P Quarterman; A Gescher; J A Slack
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.

Authors:  Takuro Hayashi; Kazuhide Adachi; Shigeo Ohba; Yuichi Hirose
Journal:  J Neurooncol       Date:  2013-08-13       Impact factor: 4.130

7.  Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.

Authors:  Monica E Loghin; Michael D Prados; Patrick Wen; Larry Junck; Frank Lieberman; Howard Fine; Karen L Fink; Minesh Metha; John Kuhn; Kathleen Lamborn; Susan M Chang; Timothy Cloughesy; Lisa M DeAngelis; Ian H Robins; Kenneth D Aldape; W K Alfred Yung
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

8.  Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities.

Authors:  Arabinda Das; Naren L Banik; Sunil J Patel; Swapan K Ray
Journal:  Mol Cancer       Date:  2004-12-08       Impact factor: 27.401

9.  Treatment of glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry.

Authors:  Klaus Braun; Manfred Wiessler; Volker Ehemann; Ruediger Pipkorn; Herbert Spring; Juergen Debus; Bernd Didinger; Mario Koch; Gabriele Muller; Waldemar Waldeck
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

Review 10.  A narrative review of research progress on drug therapies for glioblastoma multiforme.

Authors:  Xiangjin Zheng; Qin Tang; Liwen Ren; Jinyi Liu; Wan Li; Weiqi Fu; Jinhua Wang; Guanhua Du
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.